Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Lymphoma
Multiple Myeloma
Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma

Interventions: Drug: Maplirpacept (PF-07901801)
Drug: Anti-CD20 Targeting agent
Drug: Azacitidine
Drug: Carfilzomib
Drug: Venetoclax
Drug: Dexamethasone
Drug: Isatuximab

First Posted Date: 2018-05-21

Last Posted Date: 2023-12-22

Lead Sponsor: Pfizer

Target Recruit Count: 177

Registration Number: NCT03530683

Locations: 🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northside Hospital, Atlanta, Georgia, United States

and more 58 locations

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

Phase 2

Completed

Conditions: Respiratory Tract Infections

Interventions: Biological: Formulation B
Biological: Formulation A
Biological: Placebo

First Posted Date: 2018-05-18

Last Posted Date: 2022-03-03

Lead Sponsor: Pfizer

Target Recruit Count: 1235

Registration Number: NCT03529773

Locations: 🇺🇸
Meridian Clinical Research, Savannah, Georgia, United States
🇺🇸
Meridian Clinical Research Dakota Dunes, Sioux City, Iowa, United States
🇺🇸
Aventiv Research Inc., Columbus, Ohio, United States

and more 34 locations

A Study of PF-06873600 in People With Cancer

Phase 1

Terminated

Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

Interventions: Drug: PF-06873600
Drug: Endocrine Therapy 1
Drug: Endocrine Therapy 2

First Posted Date: 2018-05-08

Last Posted Date: 2025-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 155

Registration Number: NCT03519178

Locations: 🇺🇸
UCLA Hematology/Oncology - Parkside, Santa Monica, California, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States

and more 42 locations

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease
Non-alcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: PF-06865571

First Posted Date: 2018-05-01

Last Posted Date: 2020-03-13

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT03513588

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States

and more 3 locations

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

Phase 2

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: 13vPnC
Biological: Multivalent

First Posted Date: 2018-04-30

Last Posted Date: 2021-03-02

Lead Sponsor: Pfizer

Target Recruit Count: 460

Registration Number: NCT03512288

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸
Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
🇺🇸
Pediatric Associates of Mt. Carmel, Inc., Cincinnati, Ohio, United States

and more 32 locations

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Tofacitinib

First Posted Date: 2018-04-18

Last Posted Date: 2021-09-17

Lead Sponsor: Pfizer

Target Recruit Count: 270

Registration Number: NCT03502616

Locations: 🇨🇦
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc., Quebec, Canada
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

and more 96 locations

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2

Terminated

Conditions: Early Breast Cancer

Interventions: Drug: TALAZOPARIB

First Posted Date: 2018-04-17

Last Posted Date: 2021-11-09

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT03499353

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Thornton, Colorado, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 65 locations

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: PF-06882961 Immediate Release Tablet
Drug: PF-06882961 Controlled Release Tablet (long)
Drug: PF-06882961 Controlled Release Tablet (short)
Drug: PF-06882961 Immediate Release Solution

First Posted Date: 2018-04-10

Last Posted Date: 2018-07-30

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03492697

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Anaemetro I.V. Infusion 500mg Drug Use Investigation

Completed

Conditions: Anaerobic Infection
Infectious Enterocolitis
Amebic Dysentery

First Posted Date: 2018-04-09

Last Posted Date: 2018-12-28

Lead Sponsor: Pfizer

Target Recruit Count: 107

Registration Number: NCT03491228

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Other: Placebo
Drug: Tofacitinib

First Posted Date: 2018-04-03

Last Posted Date: 2024-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 204

Registration Number: NCT03486457

Locations: 🇨🇳
The Third Hospital of Hebei Medical University, Rheumatology and Immunology Department, Shijiazhuang, Hebei, China
🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy